Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia
Lu AA24493 is a novel carbamoylated form of human erythropoietin (EPO) - a modification of EPO that results in loss of haematopoietic effects but maintains the tissue protective effect. These tissue protective effects translate to very positive effects in a number of animal models for neuronal damage
The primary objective of the study is to evaluate the safety and tolerability of two weeks treatment with a fixed dose Lu AA24493 in patients with Friedreich's ataxia. However, this placebo-controlled programme may also potentially provide efficacy signals via biomarkers.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.